- Home
- TEVA
as 07-18-2025 4:00pm EST
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 20.1B | IPO Year: | N/A |
| Target Price: | $24.71 | AVG Volume (30 days): | 9.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.46 - $22.80 | Next Earning Date: | 07-30-2025 |
| Revenue: | $16,616,000,000 | Revenue Growth: | 3.82% |
| Revenue Growth (this year): | 5.69% | Revenue Growth (next year): | N/A |
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
Teva Releases Q2 2025 Aide Memoire
Insider Monkey
23 days ago
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
GlobeNewswire
23 days ago
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
Motley Fool
24 days ago
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
Clinical Trials Arena
24 days ago
Teva reports final analysis of migraine prevention trial of Ajovy
Insider Monkey
25 days ago
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
Zacks
25 days ago
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
GlobeNewswire
a month ago
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
Compare TEVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.